BiotechTube

Rilzabrutinib

Phase 1Completed
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatic Function Abnormal

Conditions

Hepatic Function Abnormal, Healthy Volunteers

Trial Timeline

Nov 2, 2020 → Mar 23, 2021

NCT ID
NCT06444204

About Rilzabrutinib

Rilzabrutinib is a phase 1 stage product being developed by Sanofi for Hepatic Function Abnormal. The current trial status is completed. This product is registered under clinical trial identifier NCT06444204. Target conditions include Hepatic Function Abnormal, Healthy Volunteers.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (6)

NCT IDPhaseStatus
NCT07007962Phase 3Recruiting
NCT07216079Phase 3Active
NCT05002777Phase 2Active
NCT06444191Phase 1Completed
NCT06444204Phase 1Completed
NCT03395210Phase 2Completed

Competing Products

20 competing products in Hepatic Function Abnormal

See all competitors
ProductCompanyStageHype Score
ITF2357BiotrialPhase 1
25
GB1211 + PlaceboComac MedicalPhase 1/2
33
ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results)IdorsiaPhase 1
28
OlomorasibEli LillyPhase 1
33
SimufilamCassava SciencesPhase 1
25
cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
77
exatecan mesylateDaiichi SankyoPhase 2
52
DS-3201bDaiichi SankyoPhase 1
33
QuizartinibDaiichi SankyoPhase 1
33
QuizartinibDaiichi SankyoPhase 1
33
PexidartinibDaiichi SankyoPhase 1
33
Tivantinib + Tivantinib + Tivantinib + TivantinibDaiichi SankyoPhase 1
33
BocidelparAstellas PharmaPhase 1
33
fezolinetantAstellas PharmaPhase 1
33
enzalutamideAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP2215Astellas PharmaPhase 1
33
BPN14770ShionogiPhase 1
33
S-217622ShionogiPhase 1
33
LemborexantEisaiPhase 1
33

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84